keyword
MENU ▼
Read by QxMD icon Read
search

Schizophrenia stimulants

keyword
https://www.readbyqxmd.com/read/28541645/raloxifene-plus-antipsychotics-versus-placebo-plus-antipsychotics-in-severely-ill-decompensated-postmenopausal-women-with-schizophrenia-or-schizoaffective-disorder-a-randomized-controlled-trial
#1
Mark Weiser, Linda Levi, Shimon Burshtein, Michal Hagin, Valentin P Matei, Delia Podea, Ioana Micluția, Alexandru Tiugan, Bogdan Păcală, Iosif Gabos Grecu, Adam Noy, Daisy Zamora, John M Davis
OBJECTIVE: Several single-center studies have found raloxifene, an estrogen agonist, to be effective in ameliorating symptoms of schizophrenia in stable patients as augmentation of antipsychotics. This multicenter study assessed whether raloxifene plus antipsychotic treatment, in comparison to placebo plus antipsychotics, improves symptoms or cognition in severely ill decompensated schizophrenia patients. METHODS: In this 16-week, double-blind, randomized, placebo-controlled study, 200 severely ill, decompensated postmenopausal women who met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were recruited from January 2011 to December 2012 and were randomized to receive either raloxifene 120 mg/d plus antipsychotics or placebo plus antipsychotics...
May 23, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28539393/phencyclidine-pcp-administration-during-neurodevelopment-alters-network-activity-in-prefrontal-cortex-and-hippocampus-in-adult-rats
#2
Celia Kjaerby, Nanna Hovelsø, Nils Ole Dalby, Florence Sotty
Symptoms of schizophrenia have been linked to insults during neurodevelopment such as NMDA receptor antagonist exposure. In animal models, this leads to schizophrenia-like behavioral symptoms as well as molecular and functional changes within hippocampal and prefrontal regions. The aim of this study was to determine how administration with the NMDA receptor antagonist, phencyclidine (PCP), during neurodevelopment affects functional network changes within the hippocampus and medial prefrontal cortex (mPFC). We recorded field potentials in vivo following electrical brainstem stimulation and observed a suppression of evoked theta power in ventral hippocampus, while evoked gamma power in mPFC was enhanced in rats administered neonatally with PCP...
May 24, 2017: Journal of Neurophysiology
https://www.readbyqxmd.com/read/28527566/abnormalities-in-high-energy-phosphate-metabolism-in-first-episode-bipolar-disorder-measured-using-31-p-magnetic-resonance-spectroscopy
#3
Fei Du, Cagri Yuksel, Virginie-Anne Chouinard, Polly Huynh, Kyle Ryan, Bruce M Cohen, Dost Öngür
BACKGROUND: Brain energy metabolism is critical for supporting synaptic function and information processing. A growing body of evidence suggests abnormalities in brain bioenergetics in psychiatric disorders, including both bipolar disorder (BD) and schizophrenia. (31)P magnetic resonance spectroscopy provides a noninvasive window into these processes in vivo. Using this approach, we previously showed that patients with BD show normal adenosine triphosphate (ATP) and phosphocreatine levels at rest but cannot maintain normal ATP levels in the visual cortex during times of high energy demand (photic stimulation)...
April 7, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28523977/the-application-of-deep-brain-stimulation-in-the-treatment-of-psychiatric-disorders
#4
Ilse Graat, Martijn Figee, Damiaan Denys
Deep brain stimulation (DBS) is a last-resort treatment for neurological and psychiatric disorders that are refractory to standard treatment. Over the last decades, the progress of DBS in psychiatry has been slower than in neurology, in part owing to the heterogenic symptomatology and complex neuroanatomy of psychiatric disorders. However, for obsessive-compulsive disorder (OCD) DBS is now an accepted treatment. This study first reviews clinical outcomes and mechanisms of DBS for OCD, and then discusses these results in an overview of current and future psychiatric applications, including DBS for mood disorders, Tourette's syndrome, addiction, anorexia nervosa, autism, schizophrenia, and anxiety disorders...
April 2017: International Review of Psychiatry
https://www.readbyqxmd.com/read/28521049/22q11-2-deletion-syndrome-is-associated-with-impaired-auditory-steady-state-gamma-response
#5
Kit Melissa Larsen, Giovanni Pellegrino, Michelle Rosgaard Birknow, Trine Nørgaard Kjær, William Frans Christiaan Baaré, Michael Didriksen, Line Olsen, Thomas Werge, Morten Mørup, Hartwig Roman Siebner
Background: The 22q11.2 deletion syndrome confers a markedly increased risk for schizophrenia. 22q11.2 deletion carriers without manifest psychotic disorder offer the possibility to identify functional abnormalities that precede clinical onset. Since schizophrenia is associated with a reduced cortical gamma response to auditory stimulation at 40 Hz, we hypothesized that the 40 Hz auditory steady-state response (ASSR) may be attenuated in nonpsychotic individuals with a 22q11.2 deletion...
May 17, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28500770/the-role-of-melatonin-in-the-neurodevelopmental-etiology-of-schizophrenia-a-study-in-human-olfactory-neuronal-precursors
#6
Tania Galván-Arrieta, Citlali Trueta, Montserrat G Cercós, Marcela Valdés-Tovar, Salvador Alarcón, Julian Oikawa, Horacio Zamudio-Meza, Gloria Benítez-King
Dim light exposure of the mother during pregnancy has been proposed as one of the environmental factors that affect the fetal brain development in schizophrenia. Melatonin circulating levels are regulated by the environmental light/dark cycle. This hormone stimulates neuronal differentiation in the adult brain. However, little is known about its role in the fetal human brain development. Olfactory neuronal precursors (ONPs) are useful for studying the physiopathology of neuropsychiatric diseases because they mimic all the stages of neurodevelopment in culture...
May 13, 2017: Journal of Pineal Research
https://www.readbyqxmd.com/read/28478887/investigating-the-neurobiology-of-schizophrenia-and-other-major-psychiatric-disorders-with-transcranial-magnetic-stimulation
#7
REVIEW
Rachel E Kaskie, Fabio Ferrarelli
Characterizing the neurobiology of schizophrenia and other major psychiatric disorders is one of the main challenges of the current research in psychiatry. The availability of Transcranial Magnetic Stimulation (TMS) allows to directly probe virtually any cortical areas, thus providing a unique way to assess the neurophysiological properties of cortical neurons. This article presents a review of studies employing TMS in combination with Motor Evoked Potentials (TMS/MEPs) and high density Electroencephalogram (TMS/hd-EEG) in schizophrenia and other major psychiatric disorders...
May 3, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28473777/investigating-the-role-of-serotonin-in-methamphetamine-psychosis-unaltered-behavioral-effects-of-chronic-methamphetamine-in-5-ht1a-knockout-mice
#8
Emily J Jaehne, Dzeneta Ameti, Tehani Paiva, Maarten van den Buuse
Methamphetamine (Meth) is a widely abused stimulant drug, but this abuse is associated with an increased risk of developing psychosis. In addition to its well-known action on brain dopamine, Meth also affects serotonergic (5-HT) neurons. The aim of this study was to investigate this role in mice, which lack one of the main serotonin receptors, the 5-HT1A receptor, which has been implicated in both schizophrenia and Meth-induced psychosis. Male and female wild-type or 5-HT1A knockout (KO) mice received daily treatment with increasing doses of methamphetamine from 6 to 9 weeks of age (1-4 mg/kg/day twice a day)...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28464965/risk-of-transition-to-schizophrenia-following-first-admission-with-substance-induced-psychotic-disorder-a-population-based-longitudinal-cohort-study
#9
H L Alderson, D M Semple, C Blayney, F Queirazza, V Chekuri, S M Lawrie
BACKGROUND: The potential for drugs of abuse to induce acute psychotic symptoms is well recognised. However, the likelihood of transition from initial substance-induced psychotic disorder (SIPD) to chronic psychosis is much less well understood. This study investigated the rate of SIPD transition to schizophrenia (F20), the time to conversion and other possible related factors. METHODS: Using data from the Scottish Morbidity Record, we examined all patients (n = 3486) since their first admission to psychiatric hospital with a diagnosis of SIPD [International Classification of Diseases, Tenth Revision (ICD-10) codes F10-F19, with third digit five] from January 1997 to July 2012...
May 3, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28455126/neurochemical-arguments-for-the-use-of-dopamine-d4-receptor-stimulation-to-improve-cognitive-impairment-associated-with-schizophrenia
#10
Mei Huang, Sunoh Kwon, Wenqi He, Herbert Y Meltzer
BACKGROUND: Dopamine (DA) D4 receptors have been implicated in schizophrenia and the ability of some atypical antipsychotic drugs (APDs) to improve the cognitive impairment associated with schizophrenia (CIAS). Systemic administration of a D4 agonist, PD168077, at a sub-effective dose, together with a sub-effective dose of lurasidone, an atypical APD which is a weak D4 receptor antagonist, reversed the deficit in novel object recognition (NOR) in rats treated subchronically with phencyclidine (PCP), a rodent model of CIAS...
April 25, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28447622/modern-clinical-research-on-lsd
#11
REVIEW
Matthias E Liechti
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility...
April 27, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28442424/thioredoxin-is-not-a-marker-for-treatment-resistance-depression-but-associated-with-cognitive-function-an-rtms-study
#12
Efruz Pirdogan Aydın, Abdullah Genc, Mihriban Dalkıran, Ece Türkyilmaz Uyar, Ömer Akil Özer, Kayıhan Oğuz Karamustafalıoğlu
Elevated oxidative stress is known to play an important role in development of depression and cognitive dysfunction. To date, thioredoxin (TRX), an antioxidant protein, has been investigated as a marker for psychiatric disorders such as schizophrenia, bipolar disorder and autism but its relationship with depression is yet to be unknown. The aim of this study is to detect the TRX levels in patients with treatment-resistant depression (TRD), analyse the effect of rTMS (repetitive transcranial magnetic stimulation) application on TRX levels and display the relationship of TRX with cognitive areas...
April 22, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28442422/effects-of-low-frequency-rtms-treatment-on-brain-networks-for-inner-speech-in-patients-with-schizophrenia-and-auditory-verbal-hallucinations
#13
Leonie Bais, Edith Liemburg, Ans Vercammen, Richard Bruggeman, Rikus Knegtering, André Aleman
INTRODUCTION: Efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) targeting the temporo-parietal junction (TPJ) for the treatment of auditory verbal hallucinations (AVH) remains under debate. We assessed the influence of a 1Hz rTMS treatment on neural networks involved in a cognitive mechanism proposed to subserve AVH. METHODS: Patients with schizophrenia (N=24) experiencing medication-resistant AVH completed a 10-day 1Hz rTMS treatment. Participants were randomized to active stimulation of the left or bilateral TPJ, or sham stimulation...
April 22, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28425497/single-dose-memantine-improves-cortical-oscillatory-response-dynamics-in-patients-with-schizophrenia
#14
Gregory A Light, Wen Zhang, Yash B Joshi, Savita Bhakta, Jo A Talledo, Neal R Swerdlow
Aberrant gamma band (30-80 Hz) oscillations may underlie cognitive deficits in schizophrenia (SZ). Gamma oscillations and their regulation by NMDA receptors can be studied via their evoked power (γEP) and phase locking (γPL) in response to auditory steady state stimulation; these Auditory Steady State Responses (ASSRs) may be biomarkers for target engagement and early therapeutic effects. We previously reported that memantine, an NMDA receptor antagonist, enhanced 2 biomarkers of early auditory information processing: prepulse inhibition (PPI) and mismatch negativity (MMN) in SZ patients and healthy subjects (HS)...
April 20, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28419874/oral-administration-of-a-specific-kynurenic-acid-synthesis-kat-ii-inhibitor-attenuates-evoked-glutamate-release-in-rat-prefrontal-cortex
#15
D M Bortz, H-Q Wu, R Schwarcz, J P Bruno
Cognitive deficits represent core symptoms in schizophrenia (SZ) and predict patient outcome; however, they remain poorly treated by current antipsychotic drugs. Elevated levels of the endogenous alpha7 nicotinic receptor negative allosteric modulator and NMDA receptor antagonist, kynurenic acid (KYNA), are commonly seen in post-mortem tissue and cerebrospinal fluid of patients with SZ. When acutely or chronically elevated in rodents, KYNA produces cognitive deficits similar to those seen in the disease, making down-regulation of KYNA, via inhibition of kynurenine aminotransferase II (KAT II), a potential treatment strategy...
April 15, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28416594/new-repeat-polymorphism-in-the-akt1-gene-predicts-striatal-dopamine-d2-d3-receptor-availability-and-stimulant-induced-dopamine-release-in-the-healthy-human-brain
#16
Elena Shumay, Corinde E Wiers, Ehsan Shokri-Kojori, Sung Won Kim, Colin A Hodgkinson, Hui Sun, Dardo Tomasi, Christopher T Wong, Daniel R Weinberger, Gene-Jack Wang, Joanna S Fowler, Nora D Volkow
The role of the protein kinase Akt1 in dopamine neurotransmission is well recognized and has been implicated in schizophrenia and psychosis. However, the extent to which variants in the AKT1 gene influence dopamine neurotransmission is not well understood. Here we investigated the effect of a newly characterized variant number tandem repeat (VNTR) polymorphism in AKT1 [major alleles: L- (eight repeats) and H- (nine repeats)] on striatal dopamine D2/D3 receptor (DRD2) availability and on dopamine release in healthy volunteers...
May 10, 2017: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/28411046/different-influence-of-antipsychotics-on-the-balance-between-pro-and-anti-inflammatory-cytokines-depends-on-glia-activation-an-in-vitro-study
#17
Ewa Obuchowicz, Anna M Bielecka-Wajdman, Monika Paul-Samojedny, Marta Nowacka
The microglial hypothesis of schizophrenia suggests that its neuropathology is closely associated with neuroinflammation manifested, inter alia, by an increased expression of cytokines. However, clinical investigations imply that schizophrenia is a heterogeneous disease and in some groups of patients the activated inflammatory process does not contribute to the disease-associated impairment of brain function. Clinical studies revealed also an equivocal impact of antipsychotics on peripheral and CSF cytokines, whereas experimental research performed on the stimulated glia cultures showed their inhibitory effect on pro-inflammatory cytokine levels...
April 11, 2017: Cytokine
https://www.readbyqxmd.com/read/28397113/managing-negative-symptoms-of-schizophrenia-how-far-have-we-come
#18
REVIEW
Joshua T Kantrowitz
The specific efficacy of antipsychotics on negative symptoms is questionable, suggesting an urgent need for specific treatments for negative symptoms. This review includes studies published since 2014 with a primary or secondary focus on treating negative symptoms in schizophrenia. Special emphasis is given to recently published meta-analyses. Topics include novel pharmacological approaches, including glutamatergic-based and nicotinic-acetylcholinergic treatments, treatments approved for other indications by the US FDA (or other regulatory bodies) (antipsychotics, antidepressants, and mood stabilizers), brain stimulation, and behavioral- and activity-based approaches, including physical exercise...
May 2017: CNS Drugs
https://www.readbyqxmd.com/read/28393897/olanzapine-but-not-clozapine-increases-glutamate-release-in-the-prefrontal-cortex-of-freely-moving-mice-by-inhibiting-d-aspartate-oxidase-activity
#19
Silvia Sacchi, Vito De Novellis, Giovanna Paolone, Tommaso Nuzzo, Monica Iannotta, Carmela Belardo, Marta Squillace, Paolo Bolognesi, Elena Rosini, Zoraide Motta, Martina Frassineti, Alessandro Bertolino, Loredano Pollegioni, Michele Morari, Sabatino Maione, Francesco Errico, Alessandro Usiello
D-aspartate levels in the brain are regulated by the catabolic enzyme D-aspartate oxidase (DDO). D-aspartate activates NMDA receptors, and influences brain connectivity and behaviors relevant to schizophrenia in animal models. In addition, recent evidence reported a significant reduction of D-aspartate levels in the post-mortem brain of schizophrenia-affected patients, associated to higher DDO activity. In the present work, microdialysis experiments in freely moving mice revealed that exogenously administered D-aspartate efficiently cross the blood brain barrier and stimulates L-glutamate efflux in the prefrontal cortex (PFC)...
April 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28379529/reduced-short-latency-afferent-inhibition-in-prefrontal-but-not-motor-cortex-and-its-association-with-executive-function-in-schizophrenia-a-combined-tms-eeg-study
#20
Yoshihiro Noda, Mera S Barr, Reza Zomorrodi, Robin F H Cash, Tarek K Rajji, Faranak Farzan, Robert Chen, Tony P George, Zafiris J Daskalakis, Daniel M Blumberger
BACKGROUND: Cholinergic dysfunction is increasingly assumed to be involved in the pathophysiology of schizophrenia. Short-latency afferent inhibition (SAI) is a transcranial magnetic stimulation (TMS) paradigm that has been shown to assay central cholinergic activity from the motor cortex (M1). Recently, we established a method to index SAI from the dorsolateral prefrontal cortex (DLPFC), an area implicated in the pathophysiology of schizophrenia. We investigated SAI in M1 and DLPFC in schizophrenia...
April 1, 2017: Schizophrenia Bulletin
keyword
keyword
77681
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"